Coagulant Therapeutics is developing medicines to treat acute bleeding, an unmet medical need that includes postpartum hemorrhage, intracranial hemorrhage, traumatic brain injury and trauma, through it’s expertise and experience in both the coagulation cascade and biologics.
Acute bleeding is an unmet need with no approved treatments.
-
The leading cause of death ages 1-46 is Acute Bleeding associated with traumatic injury*
-
20-40% of hemorrhage related deaths are potentially preventable with rapid hemostatic control**
-
There are currently no approved drugs to treat acute bleeding
*Centers for Disease Control and Prevention, National Center for Injury Prevention and Control
**Tisherman et al., 2015. Ann Surg. 2015 Mar; 261(3): 586–590.
CT-001 – A Novel Factor VIIa
Building on the proven clinical activity of FVIIa to stop bleeds, we have engineered the molecule to both enhance its activity and engineered in additional safety measures to ensure the balance of enhanced potency with increased safety for acute bleeding. A highly potent and safe FVIIa approach could serve a large potential patient population.
Experts in coagulation cascade and biologics developing hemostatic agents to treat acute bleeding.
Leveraging 100+ years of collective experience and leveraging assets including over 30 patents acquired from Bayer AG and Maxygen, Coagulant Therapeutics has developed an optimized and proprietary rFVIIa molecule, termed CT-001, for the safe and effective pharmaceutical intervention for the treatment of acute bleeding.